NEW YORK, NY--(Marketwire -03/12/12)- The biotechnology industry has been on an impressive run this year as companies -- both large and small -- show impressive growth. The iShares Nasdaq Biotechnology Index (IBB) Fund is outperforming the broader market by a wide margin and is up more than 14 percent this year. The Paragon Report examines investing opportunities in the Biotechnology Industry and provides equity research on Dendreon Corporation (NASDAQ: DNDN - News) & Arena Pharmaceuticals Inc. (NASDAQ: ARNA - News). Access to the full company reports can be found at:

http://www.paragonreport.com/DNDN

http://www.paragonreport.com/ARNA

Last week, The Biotechnology Industry Organization (BIO) -- which represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations -- applauded the U.S. House on the passage of H.R. 3606, the Jumpstart Our Business Startups (JOBS) Act and explained the legislation's significance on the biotech industry. According to BIO, provisions of the Act would make the pathway to capital formation more attainable for small biotechnology companies.

"This legislation would make capital formation easier for small biotechnology companies, enabling them to focus more on curing and treating disease," BIO President and CEO Jim Greenwood said in a statement.

The Paragon Report provides investors with an excellent first step in their due diligence by providing daily trading ideas, and consolidating the public information available on them. For more investment research on the biotechnology industry register with us free at http://www.paragonreport.com and get exclusive access to our numerous stock reports and industry newsletters.

Larger biotech firms, meanwhile, are looking to rein in costs and plan to outsource R&D and clinical trials and shift this work overseas to places such as China and India, according to a survey released by global consulting firm Booz & Company. The study says that many biopharmaceutical companies will begin outsourcing formerly core activities such as clinical trial monitoring and protocol development to contract research organizations (CROs).

According to the survey, companies are outsourcing for three main reasons: They lack certain internal capabilities (53 percent), they lack internal capacity (38 percent), and they need to cut costs (44 percent).

The Paragon Report has not been compensated by any of the above-mentioned publicly traded companies. Paragon Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at http://www.paragonreport.com/disclaimer

See the rest here:
Biotech Industry Poised for Growth -- Dendreon and Arena Pharmaceuticals Looking Strong